Skip to main content
Erschienen in: Clinical Pharmacokinetics 15/2003

01.12.2003 | Review Article

Stereoselectivity in the Pharmacodynamics and Pharmacokinetics of the Chiral Antimalarial Drugs

verfasst von: Dr Dion R. Brocks, Reza Mehvar

Erschienen in: Clinical Pharmacokinetics | Ausgabe 15/2003

Einloggen, um Zugang zu erhalten

Abstract

Several of the antimalarial drugs are chiral and administered as the racemate. These drugs include chloroquine, hydroxychloroquine, quinacrine, primaquine, mefloquine, halofantrine, lumefantrine and tafenoquine. Quinine and quinidine are also stereoisomers, although they are given separately rather than in combination.
From the perspective of antimalarial activity, most of these agents demonstrate little stereoselectivity in their effects in vitro. Mefloquine, on the other hand, displays in vitro stereoselectivity against some strains of P. falciparum, with a eudismic ratio of almost 2: 1 in favour of the (+)-enantiomer. Additionally, for some of these agents (e.g. halofantrine, primaquine, chloroquine), stereoselectivity has been noted in the ability of the enantiomers to cause certain adverse effects.
In recent years, stereospecific analytical methods capable of measuring the individual enantiomers after the administration of racemic drugs have been reported for a number of chiral antimalarial drugs. These assays have revealed that almost all the studied antimalarial drugs display stereoselectivity in their pharmacokinetics, leading to enantioselectivity in their plasma concentrations. Whereas the oral absorption of these agents appears to be non-stereoselective, stereoselectivity is often seen in their volume of distribution and/or clearance. With regard to distribution, plasma protein binding of some chiral antimalarial drugs exhibits a significant degree of stereoselectivity, leading to stereoselective distribution to blood cells and other tissues. Because of their low hepatic extraction ratios, stereoselective plasma protein binding also contributes to the stereoselectivity in the metabolism of these drugs. Chiral metabolites are formed from some parent antimalarial drugs, although stereoselective aspects of the pharmacokinetics of the metabolites are not well understood.
It is concluded that knowledge of the stereoselective aspects of these agents may be helpful in better understanding their mechanisms of action and possibly optimising their clinical safety and/or effectiveness.
Literatur
1.
Zurück zum Zitat Anon. World malaria situation in 1994: Pt I. Population at risk. Wkly Epidemiol Rec 1997; 72: 269–74 Anon. World malaria situation in 1994: Pt I. Population at risk. Wkly Epidemiol Rec 1997; 72: 269–74
2.
Zurück zum Zitat Anon. Malaria, 1982–1997. Wkly Epidemiol Rec 1999; 74: 265-70 Anon. Malaria, 1982–1997. Wkly Epidemiol Rec 1999; 74: 265-70
3.
Zurück zum Zitat Anon. Malaria: general information. National Center for Infectious Diseases Travellers’s Health 2000 Anon. Malaria: general information. National Center for Infectious Diseases Travellers’s Health 2000
4.
Zurück zum Zitat Hoffman SL, Subramanian GM, Collins FH, et al. Plasmodium, human and Anopheles genomics and malaria. Nature 2002; 415: 702–9PubMedCrossRef Hoffman SL, Subramanian GM, Collins FH, et al. Plasmodium, human and Anopheles genomics and malaria. Nature 2002; 415: 702–9PubMedCrossRef
5.
Zurück zum Zitat Baird JK. Resurgent malaria at the millennium: control strategies in crisis. Drugs 2000; 59: 719–43PubMedCrossRef Baird JK. Resurgent malaria at the millennium: control strategies in crisis. Drugs 2000; 59: 719–43PubMedCrossRef
6.
Zurück zum Zitat Ridley RG. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 2002; 415: 686–93PubMedCrossRef Ridley RG. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 2002; 415: 686–93PubMedCrossRef
7.
Zurück zum Zitat Brocks DR, Jamali F. Stereochemical aspects of pharmacotherapy. Pharmacotherapy 1995; 15: 551–64PubMed Brocks DR, Jamali F. Stereochemical aspects of pharmacotherapy. Pharmacotherapy 1995; 15: 551–64PubMed
8.
Zurück zum Zitat Jamali F, Mehvar R, Pasutto FM. Enantioselective aspects of drug action and disposition: therapeutic pitfalls. J Pharm Sci 1989; 78: 695–715PubMedCrossRef Jamali F, Mehvar R, Pasutto FM. Enantioselective aspects of drug action and disposition: therapeutic pitfalls. J Pharm Sci 1989; 78: 695–715PubMedCrossRef
9.
Zurück zum Zitat Tracy TS. Stereochemistry in pharmacotherapy: when mirror images are not identical. Ann Pharmacother 1995; 29: 161–5PubMed Tracy TS. Stereochemistry in pharmacotherapy: when mirror images are not identical. Ann Pharmacother 1995; 29: 161–5PubMed
10.
Zurück zum Zitat Wainer IW, Marcotte AA. Stereochemical terms and concepts, an overview. In: Wainer IW, editor. Drug stereochemistry: analytical methods and pharmacology. 2nd ed. New York: Dekker, 1993: 25–34 Wainer IW, Marcotte AA. Stereochemical terms and concepts, an overview. In: Wainer IW, editor. Drug stereochemistry: analytical methods and pharmacology. 2nd ed. New York: Dekker, 1993: 25–34
11.
Zurück zum Zitat Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine: focus on recent advancements. Clin Pharmacokinet 1996; 31: 257–74PubMedCrossRef Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine: focus on recent advancements. Clin Pharmacokinet 1996; 31: 257–74PubMedCrossRef
12.
Zurück zum Zitat Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine: clinical implications. Clin Pharmacokinet 1996; 30: 263–99PubMedCrossRef Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine: clinical implications. Clin Pharmacokinet 1996; 30: 263–99PubMedCrossRef
13.
Zurück zum Zitat White NJ. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet 1985; 10: 187–215PubMedCrossRef White NJ. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet 1985; 10: 187–215PubMedCrossRef
14.
Zurück zum Zitat Edwards G, Winstanley PA, Ward SA. Clinical pharmacokinetics in the treatment of tropical diseases: some applications and limitations. Clin Pharmacokinet 1994; 27: 150–65PubMedCrossRef Edwards G, Winstanley PA, Ward SA. Clinical pharmacokinetics in the treatment of tropical diseases: some applications and limitations. Clin Pharmacokinet 1994; 27: 150–65PubMedCrossRef
15.
Zurück zum Zitat White NJ. Antimalarial pharmacokinetics and treatment regimens. Br J Clin Pharmacol 1992; 34: 1–10PubMedCrossRef White NJ. Antimalarial pharmacokinetics and treatment regimens. Br J Clin Pharmacol 1992; 34: 1–10PubMedCrossRef
16.
Zurück zum Zitat Tracy JW, Webster Jr LT. Drugs used in the chemotherapy of protozoal diseases: malaria. In: Hardman JG, Limbird LE, Goodman Gilman A, editors. Goodman and Gilmans’s the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001: 1069–96 Tracy JW, Webster Jr LT. Drugs used in the chemotherapy of protozoal diseases: malaria. In: Hardman JG, Limbird LE, Goodman Gilman A, editors. Goodman and Gilmans’s the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001: 1069–96
17.
Zurück zum Zitat Miller LH, Baruch DI, Marsh K, et al. The pathogenic basis of malaria. Nature 2002; 415: 673–9PubMedCrossRef Miller LH, Baruch DI, Marsh K, et al. The pathogenic basis of malaria. Nature 2002; 415: 673–9PubMedCrossRef
18.
Zurück zum Zitat Noedl H, Allmendinger T, Prajakwong S, et al. Desbutyl-benflumetol, a novel antimalarial compound: in vitro activity in fresh isolates of Plasmodium falciparum from Thailand. Antimicrob Agents Chemother 2001; 45: 2106–9PubMedCrossRef Noedl H, Allmendinger T, Prajakwong S, et al. Desbutyl-benflumetol, a novel antimalarial compound: in vitro activity in fresh isolates of Plasmodium falciparum from Thailand. Antimicrob Agents Chemother 2001; 45: 2106–9PubMedCrossRef
19.
Zurück zum Zitat Karbwang J, Na Bangchang K. Clinical pharmacokinetics of halofantrine. Clin Pharmacokinet 1994; 27: 104–19PubMedCrossRef Karbwang J, Na Bangchang K. Clinical pharmacokinetics of halofantrine. Clin Pharmacokinet 1994; 27: 104–19PubMedCrossRef
20.
Zurück zum Zitat Bray PG, Janneh O, Raynes KJ, et al. Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum. J Cell Biol 1999; 145: 363–76PubMedCrossRef Bray PG, Janneh O, Raynes KJ, et al. Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum. J Cell Biol 1999; 145: 363–76PubMedCrossRef
21.
Zurück zum Zitat Bray PG, Mungthin M, Ridley RG, et al. Access to hematin: the basis of chloroquine resistance. Mol Pharmacol 1998; 54: 170–9PubMed Bray PG, Mungthin M, Ridley RG, et al. Access to hematin: the basis of chloroquine resistance. Mol Pharmacol 1998; 54: 170–9PubMed
22.
Zurück zum Zitat Gabay T, Krugliak M, Shalmiev G, et al. Inhibition by anti-malarial drugs of haemoglobin denaturation and iron release in acidified red blood cell lysates: a possible mechanism of their anti-malarial effect? Parasitology 1994; 108 (Pt 4): 371–81PubMedCrossRef Gabay T, Krugliak M, Shalmiev G, et al. Inhibition by anti-malarial drugs of haemoglobin denaturation and iron release in acidified red blood cell lysates: a possible mechanism of their anti-malarial effect? Parasitology 1994; 108 (Pt 4): 371–81PubMedCrossRef
23.
Zurück zum Zitat Mungthin M, Bray PG, Ridley RG, et al. Central role of hemoglobin degradation in mechanisms of action of 4-amino-quinolines, quinoline methanols, and phenanthrene methanols. Antimicrob Agents Chemother 1998; 42: 2973–7PubMed Mungthin M, Bray PG, Ridley RG, et al. Central role of hemoglobin degradation in mechanisms of action of 4-amino-quinolines, quinoline methanols, and phenanthrene methanols. Antimicrob Agents Chemother 1998; 42: 2973–7PubMed
24.
Zurück zum Zitat Foley M, Tilley L. Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. Pharmacol Ther 1998; 79: 55–87PubMedCrossRef Foley M, Tilley L. Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. Pharmacol Ther 1998; 79: 55–87PubMedCrossRef
25.
Zurück zum Zitat Wong LT, Smyth DD, Sitar DS. Stereoselective inhibition of renal organic cation transport in human kidney. Br J Clin Pharmacol 1992; 34: 438–40PubMedCrossRef Wong LT, Smyth DD, Sitar DS. Stereoselective inhibition of renal organic cation transport in human kidney. Br J Clin Pharmacol 1992; 34: 438–40PubMedCrossRef
26.
Zurück zum Zitat Basco LK, Gillotin C, Gimenez F, et al. In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against Plasmodium falciparum. Br J Clin Pharmacol 1992; 33: 517–20PubMedCrossRef Basco LK, Gillotin C, Gimenez F, et al. In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against Plasmodium falciparum. Br J Clin Pharmacol 1992; 33: 517–20PubMedCrossRef
27.
Zurück zum Zitat Fu S, Bjorkman A, Wahlin B, et al. In vitro activity of chloroquine, the two enantiomers of chloroquine, desethyl-chloroquine and pyronaridine against Plasmodium falciparum. Br J Clin Pharmacol 1986; 22: 93–6PubMed Fu S, Bjorkman A, Wahlin B, et al. In vitro activity of chloroquine, the two enantiomers of chloroquine, desethyl-chloroquine and pyronaridine against Plasmodium falciparum. Br J Clin Pharmacol 1986; 22: 93–6PubMed
28.
Zurück zum Zitat Webster RV, Craig JC, Shyamala V, et al. Antimalarial activity of optical isomers of quinacrine dihydrochloride against chloroquine-sensitive and -resistant Plasmodium falciparum in vitro. Biochem Pharmacol 1991; 42 Suppl.: S225–7PubMedCrossRef Webster RV, Craig JC, Shyamala V, et al. Antimalarial activity of optical isomers of quinacrine dihydrochloride against chloroquine-sensitive and -resistant Plasmodium falciparum in vitro. Biochem Pharmacol 1991; 42 Suppl.: S225–7PubMedCrossRef
29.
Zurück zum Zitat Karle JM, Olmeda R, Gerena L, et al. Plasmodium falciparum: role of absolute stereochemistry in the antimalarial activity of synthetic amino alcohol antimalarial agents. Exp Parasitol 1993; 76: 345–51PubMedCrossRef Karle JM, Olmeda R, Gerena L, et al. Plasmodium falciparum: role of absolute stereochemistry in the antimalarial activity of synthetic amino alcohol antimalarial agents. Exp Parasitol 1993; 76: 345–51PubMedCrossRef
30.
Zurück zum Zitat Wernsdorfer WH, Landgraf B, Kilimali VA, et al. Activity of benflumetol and its enantiomers in fresh isolates of Plasmodium falciparum from East Africa. Acta Trop 1998; 70: 9–15PubMedCrossRef Wernsdorfer WH, Landgraf B, Kilimali VA, et al. Activity of benflumetol and its enantiomers in fresh isolates of Plasmodium falciparum from East Africa. Acta Trop 1998; 70: 9–15PubMedCrossRef
31.
Zurück zum Zitat Scaria PV, Craig JC, Shafer RH. Differential binding of the enantiomers of chloroquine and quinacrine to polynucleotides: implications for stereoselective metabolism. Biopolymers 1993; 33: 887–95PubMedCrossRef Scaria PV, Craig JC, Shafer RH. Differential binding of the enantiomers of chloroquine and quinacrine to polynucleotides: implications for stereoselective metabolism. Biopolymers 1993; 33: 887–95PubMedCrossRef
32.
Zurück zum Zitat Bates MD, Meshnick SR, Sigler CI, et al. In vitro effects of primaquine and primaquine metabolites on exoerythrocytic stages of Plasmodium berghei. Am J Trop Med Hyg 1990; 42: 532–7PubMed Bates MD, Meshnick SR, Sigler CI, et al. In vitro effects of primaquine and primaquine metabolites on exoerythrocytic stages of Plasmodium berghei. Am J Trop Med Hyg 1990; 42: 532–7PubMed
33.
Zurück zum Zitat Schmidt LH, Alexander S, Allen L, et al. Comparison of the curative antimalarial activities and toxicities of primaquine and its d and l isomers. Antimicrob Agents Chemother 1977; 12: 51–60PubMedCrossRef Schmidt LH, Alexander S, Allen L, et al. Comparison of the curative antimalarial activities and toxicities of primaquine and its d and l isomers. Antimicrob Agents Chemother 1977; 12: 51–60PubMedCrossRef
34.
Zurück zum Zitat Brossi A, Millet P, Landau I, et al. Antimalarial activity and inhibition of monoamine oxidases A and B by exo-erythrocytic antimalarials: optical isomers of primaquine, N-acylated congeners, primaquine metabolites and 5-phenoxy-substituted analogues. FEBS Lett 1987; 214: 291–4PubMedCrossRef Brossi A, Millet P, Landau I, et al. Antimalarial activity and inhibition of monoamine oxidases A and B by exo-erythrocytic antimalarials: optical isomers of primaquine, N-acylated congeners, primaquine metabolites and 5-phenoxy-substituted analogues. FEBS Lett 1987; 214: 291–4PubMedCrossRef
35.
Zurück zum Zitat Bjorkman A, Willcox M, Marbiah N, et al. Susceptibility of Plasmodium falciparum to different doses of quinine in vivo and to quinine and quinidine in vitro in relation to chloroquine in Liberia. Bull World Health Organ 1991; 69: 459–65PubMed Bjorkman A, Willcox M, Marbiah N, et al. Susceptibility of Plasmodium falciparum to different doses of quinine in vivo and to quinine and quinidine in vitro in relation to chloroquine in Liberia. Bull World Health Organ 1991; 69: 459–65PubMed
36.
Zurück zum Zitat Philipps J, Radloff PD, Wernsdorfer W, et al. Follow-up of the susceptibility of Plasmodium falciparum to antimalarials in Gabon. Am J Trop Med Hyg 1998; 58: 612–8PubMed Philipps J, Radloff PD, Wernsdorfer W, et al. Follow-up of the susceptibility of Plasmodium falciparum to antimalarials in Gabon. Am J Trop Med Hyg 1998; 58: 612–8PubMed
37.
Zurück zum Zitat Menezes CM, Kirchgatter K, Di Santi SM, et al. In vitro evaluation of quinidine sensitivity in Brazilian Plasmodium falciparum isolates: comparative analysis to quinine and chloroquine. Rev Inst Med Trop Sao Paulo 2001; 43: 221–6PubMedCrossRef Menezes CM, Kirchgatter K, Di Santi SM, et al. In vitro evaluation of quinidine sensitivity in Brazilian Plasmodium falciparum isolates: comparative analysis to quinine and chloroquine. Rev Inst Med Trop Sao Paulo 2001; 43: 221–6PubMedCrossRef
38.
Zurück zum Zitat Karle JM, Karle IL, Gerena L, et al. Stereochemical evaluation of the relative activities of the cinchona alkaloids against Plasmodium falciparum. Antimicrob Agents Chemother 1992; 36: 1538–44PubMedCrossRef Karle JM, Karle IL, Gerena L, et al. Stereochemical evaluation of the relative activities of the cinchona alkaloids against Plasmodium falciparum. Antimicrob Agents Chemother 1992; 36: 1538–44PubMedCrossRef
39.
Zurück zum Zitat Quatraro A, Consoli G, Magno M, et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus: a new job for an old drug? Ann Intern Med 1990; 112: 678–81PubMed Quatraro A, Consoli G, Magno M, et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus: a new job for an old drug? Ann Intern Med 1990; 112: 678–81PubMed
40.
Zurück zum Zitat Emami J, Pasutto FM, Mercer JR, et al. Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats. Life Sci 1999; 64: 325–35PubMedCrossRef Emami J, Pasutto FM, Mercer JR, et al. Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats. Life Sci 1999; 64: 325–35PubMedCrossRef
41.
Zurück zum Zitat Phillips RE, Looareesuwan S, White NJ, et al. Hypoglycaemia and antimalarial drugs: quinidine and release of insulin. Br Med J (Clin Res Ed) 1986; 292: 1319–21CrossRef Phillips RE, Looareesuwan S, White NJ, et al. Hypoglycaemia and antimalarial drugs: quinidine and release of insulin. Br Med J (Clin Res Ed) 1986; 292: 1319–21CrossRef
42.
Zurück zum Zitat Davis TM, Karbwang J, Looareesuwan S, et al. Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers. Br J Clin Pharmacol 1990; 30: 397–403PubMedCrossRef Davis TM, Karbwang J, Looareesuwan S, et al. Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers. Br J Clin Pharmacol 1990; 30: 397–403PubMedCrossRef
43.
Zurück zum Zitat Ryou C, Legname G, Peretz D, et al. Differential inhibition of prion propagation by enantiomers of quinacrine. Lab Invest 2003; 83(6): 837–43PubMed Ryou C, Legname G, Peretz D, et al. Differential inhibition of prion propagation by enantiomers of quinacrine. Lab Invest 2003; 83(6): 837–43PubMed
44.
Zurück zum Zitat Wesche DL, Schuster BG, Wang WX, et al. Mechanism of cardiotoxicity of halofantrine. Clin Pharmacol Ther 2000; 67: 521–9PubMedCrossRef Wesche DL, Schuster BG, Wang WX, et al. Mechanism of cardiotoxicity of halofantrine. Clin Pharmacol Ther 2000; 67: 521–9PubMedCrossRef
45.
Zurück zum Zitat Donatelli P, Marchi G, Giuliani L, et al. Stereoselective inhibition by chloroquine of histamine N-methyltransferase in the human liver and brain. Eur J Clin Pharmacol 1994; 47: 345–9PubMedCrossRef Donatelli P, Marchi G, Giuliani L, et al. Stereoselective inhibition by chloroquine of histamine N-methyltransferase in the human liver and brain. Eur J Clin Pharmacol 1994; 47: 345–9PubMedCrossRef
46.
Zurück zum Zitat Tagoe CN, Ofori-Adjei D. Effects of chloroquine and its enantiomers on the development of rat embryos in vitro. Teratology 1995; 52: 137–42PubMedCrossRef Tagoe CN, Ofori-Adjei D. Effects of chloroquine and its enantiomers on the development of rat embryos in vitro. Teratology 1995; 52: 137–42PubMedCrossRef
47.
Zurück zum Zitat Augustijns P, Jongsma HW, Verbeke N. Transplacental distribution of chloroquine in sheep. Dev Pharmacol Ther 1991; 17: 191–9PubMed Augustijns P, Jongsma HW, Verbeke N. Transplacental distribution of chloroquine in sheep. Dev Pharmacol Ther 1991; 17: 191–9PubMed
48.
Zurück zum Zitat Costedoat-Chalumeau N, Amoura Z, Aymard G, et al. Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum 2002; 46: 1123–4PubMedCrossRef Costedoat-Chalumeau N, Amoura Z, Aymard G, et al. Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum 2002; 46: 1123–4PubMedCrossRef
49.
Zurück zum Zitat Wolfe MS, Cordero JF. Safety of chloroquine in chemosuppression of malaria during pregnancy. Br Med J (Clin Res Ed) 1985; 290: 1466–7CrossRef Wolfe MS, Cordero JF. Safety of chloroquine in chemosuppression of malaria during pregnancy. Br Med J (Clin Res Ed) 1985; 290: 1466–7CrossRef
50.
Zurück zum Zitat McGready R, Thwai KL, Cho T, et al. The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancy. Trans R Soc Trop Med Hyg 2002; 96: 180–4PubMedCrossRef McGready R, Thwai KL, Cho T, et al. The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancy. Trans R Soc Trop Med Hyg 2002; 96: 180–4PubMedCrossRef
51.
Zurück zum Zitat Agarwal S, Gupta UR, Daniel CS, et al. Susceptibility of glucose-6-phosphate dehydrogenase deficient red cells to primaquine, primaquine enantiomers, and its two putative metabolites: II. effect on red blood cell membrane, lipid peroxidation, MC-540 staining, and scanning electron microscopic studies. Biochem Pharmacol 1991; 41: 17–21PubMedCrossRef Agarwal S, Gupta UR, Daniel CS, et al. Susceptibility of glucose-6-phosphate dehydrogenase deficient red cells to primaquine, primaquine enantiomers, and its two putative metabolites: II. effect on red blood cell membrane, lipid peroxidation, MC-540 staining, and scanning electron microscopic studies. Biochem Pharmacol 1991; 41: 17–21PubMedCrossRef
52.
Zurück zum Zitat Agarwal S, Gupta UR, Gupta RC, et al. Susceptibility of glucose-6-phosphate dehydrogenase deficient red cells to primaquine enantiomers and two putative metabolites: I. effect on reduced glutathione, methemoglobin content and release of hemoglobin. Biochem Pharmacol 1988; 37: 4605–9PubMedCrossRef Agarwal S, Gupta UR, Gupta RC, et al. Susceptibility of glucose-6-phosphate dehydrogenase deficient red cells to primaquine enantiomers and two putative metabolites: I. effect on reduced glutathione, methemoglobin content and release of hemoglobin. Biochem Pharmacol 1988; 37: 4605–9PubMedCrossRef
53.
Zurück zum Zitat Shanks GD, Kain KC, Keystone JS. Malaria chemoprophylaxis in the age of drug resistance: II. drugs that may be available in the future. Clin Infect Dis 2001; 33: 381–5PubMedCrossRef Shanks GD, Kain KC, Keystone JS. Malaria chemoprophylaxis in the age of drug resistance: II. drugs that may be available in the future. Clin Infect Dis 2001; 33: 381–5PubMedCrossRef
54.
Zurück zum Zitat Basco LK, Peytavin G, Gimenez F, et al. In vitro activity of the enantiomers of N-desbutyl derivative of halofantrine. Trop Med Parasitol 1994; 45: 45–6PubMed Basco LK, Peytavin G, Gimenez F, et al. In vitro activity of the enantiomers of N-desbutyl derivative of halofantrine. Trop Med Parasitol 1994; 45: 45–6PubMed
55.
Zurück zum Zitat Basco LK, Gillotin C, Gimenez F, et al. Absence of antimalarial activity or interaction with mefloquine enantiomers in vitro of the main human metabolite of mefloquine. Trans R Soc Trop Med Hyg 1991; 85: 208–9PubMedCrossRef Basco LK, Gillotin C, Gimenez F, et al. Absence of antimalarial activity or interaction with mefloquine enantiomers in vitro of the main human metabolite of mefloquine. Trans R Soc Trop Med Hyg 1991; 85: 208–9PubMedCrossRef
56.
Zurück zum Zitat Aderounmu AF. In vitro assessment of the antimalarial activity of chloroquine and its major metabolites. Ann Trop Med Parasitol 1984; 78: 581–5PubMed Aderounmu AF. In vitro assessment of the antimalarial activity of chloroquine and its major metabolites. Ann Trop Med Parasitol 1984; 78: 581–5PubMed
57.
Zurück zum Zitat Muller D, Blaschke G. Enantioselective assay of chloroquine and its main metabolite deethyl chloroquine in human plasma by capillary electrophoresis. J Chromatogr Sci 2000; 38: 435–40PubMed Muller D, Blaschke G. Enantioselective assay of chloroquine and its main metabolite deethyl chloroquine in human plasma by capillary electrophoresis. J Chromatogr Sci 2000; 38: 435–40PubMed
58.
Zurück zum Zitat McLachlan AJ, Tett SE, Cutler DJ. High-performance liquid chromatographic separation of the enantiomers of hydroxychloroquine and its major metabolites in biological fluids using an alpha 1-acid glycoprotein stationary phase. J Chromatogr 1991; 570: 119–27PubMedCrossRef McLachlan AJ, Tett SE, Cutler DJ. High-performance liquid chromatographic separation of the enantiomers of hydroxychloroquine and its major metabolites in biological fluids using an alpha 1-acid glycoprotein stationary phase. J Chromatogr 1991; 570: 119–27PubMedCrossRef
59.
Zurück zum Zitat Iredale J, Wainer IW. Determination of hydroxychloroquine and its major metabolites in plasma using sequential achiral-chiral high-performance liquid chromatography. J Chromatogr 1992; 573: 253–8PubMedCrossRef Iredale J, Wainer IW. Determination of hydroxychloroquine and its major metabolites in plasma using sequential achiral-chiral high-performance liquid chromatography. J Chromatogr 1992; 573: 253–8PubMedCrossRef
60.
Zurück zum Zitat Wei Y, Nygard GA, Khalil SKW. A HPLC method for the separation and quantification of the enantiomers of hydroxychloroquine and its three major metabolites. J Liq Chromatogr 1994; 17: 3479–90CrossRef Wei Y, Nygard GA, Khalil SKW. A HPLC method for the separation and quantification of the enantiomers of hydroxychloroquine and its three major metabolites. J Liq Chromatogr 1994; 17: 3479–90CrossRef
61.
Zurück zum Zitat Ofori-Adjei D, Ericsson O, Lindstrom B, et al. Enantioselective analysis of chloroquine and desethylchloroquine after oral administration of racemic chloroquine. Ther Drug Monit 1986; 8: 457–61PubMedCrossRef Ofori-Adjei D, Ericsson O, Lindstrom B, et al. Enantioselective analysis of chloroquine and desethylchloroquine after oral administration of racemic chloroquine. Ther Drug Monit 1986; 8: 457–61PubMedCrossRef
62.
Zurück zum Zitat Gorichon E, Martin C, Bangchang KN, et al. Chiral chromatographic method to determine the enantiomers of halofantrine and its main chiral desbutyl metabolite in erythrocytes. J Chromatogr B Biomed Sci Appl 1998; 712: 259–62PubMedCrossRef Gorichon E, Martin C, Bangchang KN, et al. Chiral chromatographic method to determine the enantiomers of halofantrine and its main chiral desbutyl metabolite in erythrocytes. J Chromatogr B Biomed Sci Appl 1998; 712: 259–62PubMedCrossRef
63.
Zurück zum Zitat Terefe H, Blaschke G. Direct determination of the enantiomers of the antimalarial drug halofantrine and its active metabolite N-desbutylhalofantrine in human plasma. J Chromatogr B Biomed Appl 1994; 657: 238–42PubMedCrossRef Terefe H, Blaschke G. Direct determination of the enantiomers of the antimalarial drug halofantrine and its active metabolite N-desbutylhalofantrine in human plasma. J Chromatogr B Biomed Appl 1994; 657: 238–42PubMedCrossRef
64.
Zurück zum Zitat Gimenez F, Aubry AF, Farinotti R, et al. The determination of the enantiomers of halofantrine and monodesbutylhalofantrine in plasma and whole blood using sequential achiral/chiral high-performance liquid chromatography. J Pharm Biomed Anal 1992; 10: 245–50PubMedCrossRef Gimenez F, Aubry AF, Farinotti R, et al. The determination of the enantiomers of halofantrine and monodesbutylhalofantrine in plasma and whole blood using sequential achiral/chiral high-performance liquid chromatography. J Pharm Biomed Anal 1992; 10: 245–50PubMedCrossRef
65.
Zurück zum Zitat Gimenez F, Farinotti R, Thuillier A, et al. Determination of the enantiomers of mefloquine in plasma and whole blood using a coupled achiral-chiral high-performance liquid chromatographic system. J Chromatogr 1990; 529: 339–46PubMedCrossRef Gimenez F, Farinotti R, Thuillier A, et al. Determination of the enantiomers of mefloquine in plasma and whole blood using a coupled achiral-chiral high-performance liquid chromatographic system. J Chromatogr 1990; 529: 339–46PubMedCrossRef
66.
Zurück zum Zitat Brocks DR, Pasutto FM, Jamali F. Analytical and semi-preparative high-performance liquid chromatographic separation and assay of hydroxychloroquine enantiomers. J Chromatogr 1992; 581: 83–92PubMedCrossRef Brocks DR, Pasutto FM, Jamali F. Analytical and semi-preparative high-performance liquid chromatographic separation and assay of hydroxychloroquine enantiomers. J Chromatogr 1992; 581: 83–92PubMedCrossRef
67.
Zurück zum Zitat Karle JM, Olmeda R, Freeman SG, et al. Quantification of the individual enantiomer plasma concentrations of the candidate antimalarial agent N4-[2,6-dimethoxy-4-methyl-5-[(3-trifluoromethyl)phenoxy]-8-quinolinyl]-1,4-pentanediamine (WR 238,605). J Chromatogr B Biomed Appl 1995; 670: 251–7PubMedCrossRef Karle JM, Olmeda R, Freeman SG, et al. Quantification of the individual enantiomer plasma concentrations of the candidate antimalarial agent N4-[2,6-dimethoxy-4-methyl-5-[(3-trifluoromethyl)phenoxy]-8-quinolinyl]-1,4-pentanediamine (WR 238,605). J Chromatogr B Biomed Appl 1995; 670: 251–7PubMedCrossRef
68.
Zurück zum Zitat Brocks DR, Dennis MJ, Schaefer WH. A liquid chromatographic assay for the stereospecific quantitative analysis of halofantrine in human plasma. J Pharm Biomed Anal 1995; 13: 911–8PubMedCrossRef Brocks DR, Dennis MJ, Schaefer WH. A liquid chromatographic assay for the stereospecific quantitative analysis of halofantrine in human plasma. J Pharm Biomed Anal 1995; 13: 911–8PubMedCrossRef
69.
Zurück zum Zitat Wallen L, Ericsson O, Wikstrom I, et al. High-performance liquid chromatographic method for the enantioselective analysis of mefloquine in plasma and urine. J Chromatogr B Biomed Appl 1994; 655: 153–7PubMedCrossRef Wallen L, Ericsson O, Wikstrom I, et al. High-performance liquid chromatographic method for the enantioselective analysis of mefloquine in plasma and urine. J Chromatogr B Biomed Appl 1994; 655: 153–7PubMedCrossRef
70.
Zurück zum Zitat Souri E, Farsam H, Jamali F. Stereospecific determination of mefloquine in biological fluids by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 700: 215–22PubMedCrossRef Souri E, Farsam H, Jamali F. Stereospecific determination of mefloquine in biological fluids by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 700: 215–22PubMedCrossRef
71.
Zurück zum Zitat Midha KK, Hubbard JW, Rawson MJ, et al. The roles of stereochemistry and partial areas in a parallel design study to assess the bioequivalence of two formulations of hydroxychloroquine: a drug with a very long half life. Eur J Pharm Sci 1996; 28: 283–92CrossRef Midha KK, Hubbard JW, Rawson MJ, et al. The roles of stereochemistry and partial areas in a parallel design study to assess the bioequivalence of two formulations of hydroxychloroquine: a drug with a very long half life. Eur J Pharm Sci 1996; 28: 283–92CrossRef
72.
Zurück zum Zitat McLachlan AJ, Tett SE, Cutler DJ, et al. Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate. Br J Clin Pharmacol 1993; 36: 78–81PubMedCrossRef McLachlan AJ, Tett SE, Cutler DJ, et al. Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate. Br J Clin Pharmacol 1993; 36: 78–81PubMedCrossRef
73.
Zurück zum Zitat Augustijns P, Verbeke N. Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. Clin Pharmacokinet 1993; 24: 259–69PubMedCrossRef Augustijns P, Verbeke N. Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans. Clin Pharmacokinet 1993; 24: 259–69PubMedCrossRef
74.
Zurück zum Zitat Tett SE, McLachlan AJ, Cutler DJ, et al. Pharmacokinetics and pharmacodynamics of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of racemate. Chirality 1994; 6: 355–9PubMedCrossRef Tett SE, McLachlan AJ, Cutler DJ, et al. Pharmacokinetics and pharmacodynamics of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of racemate. Chirality 1994; 6: 355–9PubMedCrossRef
75.
Zurück zum Zitat Ducharme J, Fieger H, Ducharme MP, et al. Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. Br J Clin Pharmacol 1995; 40: 127–33PubMedCrossRef Ducharme J, Fieger H, Ducharme MP, et al. Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. Br J Clin Pharmacol 1995; 40: 127–33PubMedCrossRef
76.
Zurück zum Zitat Abernethy DR, Wesche DL, Barbey JT, et al. Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation. Br J Clin Pharmacol 2001; 51: 231–7PubMedCrossRef Abernethy DR, Wesche DL, Barbey JT, et al. Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation. Br J Clin Pharmacol 2001; 51: 231–7PubMedCrossRef
77.
Zurück zum Zitat Bourahla A, Martin C, Gimenez F, et al. Stereoselective pharmacokinetics of mefloquine in young children. Eur J Clin Pharmacol 1996; 50: 241–4PubMedCrossRef Bourahla A, Martin C, Gimenez F, et al. Stereoselective pharmacokinetics of mefloquine in young children. Eur J Clin Pharmacol 1996; 50: 241–4PubMedCrossRef
78.
Zurück zum Zitat Gimenez F, Pennie RA, Koren G, et al. Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. J Pharm Sci 1994; 83: 824–7PubMedCrossRef Gimenez F, Pennie RA, Koren G, et al. Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. J Pharm Sci 1994; 83: 824–7PubMedCrossRef
79.
Zurück zum Zitat Martin C, Gimenez F, Bangchang KN, et al. Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteers. Eur J Clin Pharmacol 1994; 47: 85–7PubMedCrossRef Martin C, Gimenez F, Bangchang KN, et al. Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteers. Eur J Clin Pharmacol 1994; 47: 85–7PubMedCrossRef
80.
Zurück zum Zitat Khaliq Y, Gallicano K, Tisdale C, et al. Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. Br J Clin Pharmacol 2001; 51: 591–600PubMedCrossRef Khaliq Y, Gallicano K, Tisdale C, et al. Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. Br J Clin Pharmacol 2001; 51: 591–600PubMedCrossRef
81.
Zurück zum Zitat Svensson US, Alin H, Karlsson MO, et al. Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur J Clin Pharmacol 2002; 58: 339–51PubMedCrossRef Svensson US, Alin H, Karlsson MO, et al. Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur J Clin Pharmacol 2002; 58: 339–51PubMedCrossRef
82.
Zurück zum Zitat Gimenez F, Gillotin C, Basco LK, et al. Plasma concentrations of the enantiomers of halofantrine and its main metabolite in malaria patients. Eur J Clin Pharmacol 1994; 46: 561–2PubMedCrossRef Gimenez F, Gillotin C, Basco LK, et al. Plasma concentrations of the enantiomers of halofantrine and its main metabolite in malaria patients. Eur J Clin Pharmacol 1994; 46: 561–2PubMedCrossRef
83.
Zurück zum Zitat Hellgren U, Jastrebova J, Jerling M, et al. Comparison between concentrations of racemic mefloquine, its separate enantiomers and the carboxylic acid metabolite in whole blood serum and plasma. Eur J Clin Pharmacol 1996; 51: 171–3PubMedCrossRef Hellgren U, Jastrebova J, Jerling M, et al. Comparison between concentrations of racemic mefloquine, its separate enantiomers and the carboxylic acid metabolite in whole blood serum and plasma. Eur J Clin Pharmacol 1996; 51: 171–3PubMedCrossRef
84.
Zurück zum Zitat Karbwang J, Davis TM, Looareesuwan S, et al. A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. Br J Clin Pharmacol 1993; 35: 265–71PubMedCrossRef Karbwang J, Davis TM, Looareesuwan S, et al. A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. Br J Clin Pharmacol 1993; 35: 265–71PubMedCrossRef
85.
Zurück zum Zitat McLachlan AJ, Tett SE, Cutler DJ, et al. Disposition and absorption of hydroxychloroquine enantiomers following a single dose of the racemate. Chirality 1994; 6: 360–4PubMedCrossRef McLachlan AJ, Tett SE, Cutler DJ, et al. Disposition and absorption of hydroxychloroquine enantiomers following a single dose of the racemate. Chirality 1994; 6: 360–4PubMedCrossRef
86.
Zurück zum Zitat Humberstone AJ, Porter CJ, Charman WN. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. J Pharm Sci 1996; 85: 525–9PubMedCrossRef Humberstone AJ, Porter CJ, Charman WN. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. J Pharm Sci 1996; 85: 525–9PubMedCrossRef
87.
Zurück zum Zitat Milton KA, Edwards G, Ward SA, et al. Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol 1989; 28: 71–7PubMedCrossRef Milton KA, Edwards G, Ward SA, et al. Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol 1989; 28: 71–7PubMedCrossRef
88.
Zurück zum Zitat Brocks DR, Toni JW. Pharmacokinetics of halofantrine in the rat: stereoselectivity and interspecies comparisons. Biopharm Drug Dispos 1999; 20: 165–9PubMedCrossRef Brocks DR, Toni JW. Pharmacokinetics of halofantrine in the rat: stereoselectivity and interspecies comparisons. Biopharm Drug Dispos 1999; 20: 165–9PubMedCrossRef
89.
Zurück zum Zitat Brocks DR, Wasan KM. The influence of lipids on stereoselective pharmacokinetics of halofantrine: important implications in food-effect studies involving drugs that bind to lipoproteins. J Pharm Sci 2002; 91: 1817–26PubMedCrossRef Brocks DR, Wasan KM. The influence of lipids on stereoselective pharmacokinetics of halofantrine: important implications in food-effect studies involving drugs that bind to lipoproteins. J Pharm Sci 2002; 91: 1817–26PubMedCrossRef
90.
Zurück zum Zitat Shackleford DM, Porter CJ, WN Charman. Does stereoselective lymphatic absorption contribute to the enantioselective pharmacokinetics of halofantrine in vivo? Biopharm Drug Dispos 2003; 24(4): 153–7PubMedCrossRef Shackleford DM, Porter CJ, WN Charman. Does stereoselective lymphatic absorption contribute to the enantioselective pharmacokinetics of halofantrine in vivo? Biopharm Drug Dispos 2003; 24(4): 153–7PubMedCrossRef
91.
Zurück zum Zitat Ezzet F, van Vugt M, Nosten F, et al. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 2000; 44: 697–704PubMedCrossRef Ezzet F, van Vugt M, Nosten F, et al. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 2000; 44: 697–704PubMedCrossRef
92.
Zurück zum Zitat Brocks DR, Skeith KJ, Johnston C, et al. Hematologic disposition of hydroxychloroquine enantiomers. J Clin Pharmacol 1994; 34: 1088–97PubMed Brocks DR, Skeith KJ, Johnston C, et al. Hematologic disposition of hydroxychloroquine enantiomers. J Clin Pharmacol 1994; 34: 1088–97PubMed
93.
Zurück zum Zitat Ofori-Adjei D, Ericsson O, Lindstrom B, et al. Protein binding of chloroquine enantiomers and desethylchloroquine. Br J Clin Pharmacol 1986; 22: 356–8PubMedCrossRef Ofori-Adjei D, Ericsson O, Lindstrom B, et al. Protein binding of chloroquine enantiomers and desethylchloroquine. Br J Clin Pharmacol 1986; 22: 356–8PubMedCrossRef
94.
Zurück zum Zitat McLachlan AJ, Cutler DJ, Tett SE. Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites. Eur J Clin Pharmacol 1993; 44: 481–4PubMedCrossRef McLachlan AJ, Cutler DJ, Tett SE. Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites. Eur J Clin Pharmacol 1993; 44: 481–4PubMedCrossRef
95.
Zurück zum Zitat Notterman DA, Drayer DE, Metakis L, et al. Stereoselective renal tubular secretion of quinidine and quinine. Clin Pharmacol Ther 1986; 40: 511–7PubMedCrossRef Notterman DA, Drayer DE, Metakis L, et al. Stereoselective renal tubular secretion of quinidine and quinine. Clin Pharmacol Ther 1986; 40: 511–7PubMedCrossRef
96.
Zurück zum Zitat Brocks DR. Stereoselective halofantrine and desbutylhalofantrine disposition in the rat: cardiac and plasma concentrations and plasma protein binding. Biopharm Drug Dispos 2002; 23: 9–15PubMedCrossRef Brocks DR. Stereoselective halofantrine and desbutylhalofantrine disposition in the rat: cardiac and plasma concentrations and plasma protein binding. Biopharm Drug Dispos 2002; 23: 9–15PubMedCrossRef
97.
Zurück zum Zitat Mansor SM, Molyneux ME, Taylor TE, et al. Effect of Plasmodium falciparum malaria infection on the plasma concentration of α1-acid glycoprotein and the binding of quinine in Malawian children. Br J Clin Pharmacol 1991; 32: 317–21PubMedCrossRef Mansor SM, Molyneux ME, Taylor TE, et al. Effect of Plasmodium falciparum malaria infection on the plasma concentration of α1-acid glycoprotein and the binding of quinine in Malawian children. Br J Clin Pharmacol 1991; 32: 317–21PubMedCrossRef
98.
Zurück zum Zitat Wanwimolruk S, Denton JR. Plasma protein binding of quinine: binding to human serum albumin, α1-acid glycoprotein and plasma from patients with malaria. J Pharm Pharmacol 1992; 44: 806–11PubMedCrossRef Wanwimolruk S, Denton JR. Plasma protein binding of quinine: binding to human serum albumin, α1-acid glycoprotein and plasma from patients with malaria. J Pharm Pharmacol 1992; 44: 806–11PubMedCrossRef
99.
Zurück zum Zitat Dodoo D, Omer FM, Todd J, et al. Absolute levels and ratios of proinflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to Plasmodium falciparum malaria. J Infect Dis 2002; 185: 971–9PubMedCrossRef Dodoo D, Omer FM, Todd J, et al. Absolute levels and ratios of proinflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to Plasmodium falciparum malaria. J Infect Dis 2002; 185: 971–9PubMedCrossRef
100.
Zurück zum Zitat Wainer IW, Chen JC, Parenteau H, et al. Distribution of the enantiomers of hydroxychloroquine and its metabolites in ocular tissues of the rabbit after oral administration of racemic-hydroxychloroquine. Chirality 1994; 6: 347–54PubMedCrossRef Wainer IW, Chen JC, Parenteau H, et al. Distribution of the enantiomers of hydroxychloroquine and its metabolites in ocular tissues of the rabbit after oral administration of racemic-hydroxychloroquine. Chirality 1994; 6: 347–54PubMedCrossRef
101.
Zurück zum Zitat Bertagnolio S, Tacconelli E, Camilli G, et al. Case report: retinopathy after malaria prophylaxis with chloroquine. Am J Trop Med Hyg 2001; 65: 637–8PubMed Bertagnolio S, Tacconelli E, Camilli G, et al. Case report: retinopathy after malaria prophylaxis with chloroquine. Am J Trop Med Hyg 2001; 65: 637–8PubMed
102.
Zurück zum Zitat Wei Y, Nygard GA, Ellertson SL, et al. Stereoselective disposition of hydroxychloroquine and its metabolite in rats. Chirality 1995; 7: 598–604PubMedCrossRef Wei Y, Nygard GA, Ellertson SL, et al. Stereoselective disposition of hydroxychloroquine and its metabolite in rats. Chirality 1995; 7: 598–604PubMedCrossRef
103.
Zurück zum Zitat Brocks DR, Ramaswamy M, MacInnes AI, et al. The stereoselective distribution of halofantrine enantiomers within human, dog, and rat plasma lipoproteins. Pharm Res 2000; 17: 427–31PubMedCrossRef Brocks DR, Ramaswamy M, MacInnes AI, et al. The stereoselective distribution of halofantrine enantiomers within human, dog, and rat plasma lipoproteins. Pharm Res 2000; 17: 427–31PubMedCrossRef
104.
Zurück zum Zitat Colussi D, Parisot C, Legay F, et al. Binding of artemether and lumefantrine to plasma proteins and erythrocytes. Eur J Pharm Sci 1999; 9: 9–16PubMedCrossRef Colussi D, Parisot C, Legay F, et al. Binding of artemether and lumefantrine to plasma proteins and erythrocytes. Eur J Pharm Sci 1999; 9: 9–16PubMedCrossRef
105.
Zurück zum Zitat Thummell KE, Shen DD. Appendix II. Design and optimization of dosage regimens: pharmacokinetic data. In: Hardman JG, Limbird LE, Goodman Gilman A, editors. Goodman and Gilmans’s the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001: 1917–2023 Thummell KE, Shen DD. Appendix II. Design and optimization of dosage regimens: pharmacokinetic data. In: Hardman JG, Limbird LE, Goodman Gilman A, editors. Goodman and Gilmans’s the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001: 1917–2023
106.
Zurück zum Zitat Vidrequin S, Gimenez F, Basco LK, et al. Uptake of mefloquine enantiomers into uninfected and malaria-infected erythrocytes. Drug Metab Dispos 1996; 24: 689–91PubMed Vidrequin S, Gimenez F, Basco LK, et al. Uptake of mefloquine enantiomers into uninfected and malaria-infected erythrocytes. Drug Metab Dispos 1996; 24: 689–91PubMed
107.
Zurück zum Zitat Potasman I, Beny A, Seligmann H. Neuropsychiatric problems in 2,500 long-term young travelers to the tropics. J Travel Med 2000; 7: 5–9PubMedCrossRef Potasman I, Beny A, Seligmann H. Neuropsychiatric problems in 2,500 long-term young travelers to the tropics. J Travel Med 2000; 7: 5–9PubMedCrossRef
108.
Zurück zum Zitat Javorsky DJ, Tremont G, Keitner GI, et al. Cognitive and neuropsychiatric side effects of mefloquine [letter]. J Neuropsychiatry Clin Neurosci 2001; 13: 302PubMedCrossRef Javorsky DJ, Tremont G, Keitner GI, et al. Cognitive and neuropsychiatric side effects of mefloquine [letter]. J Neuropsychiatry Clin Neurosci 2001; 13: 302PubMedCrossRef
109.
Zurück zum Zitat Pham YT, Nosten F, Farinotti R, et al. Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria. Int J Clin Pharmacol Ther 1999; 37: 58–61PubMed Pham YT, Nosten F, Farinotti R, et al. Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria. Int J Clin Pharmacol Ther 1999; 37: 58–61PubMed
110.
Zurück zum Zitat Karbwang J, White NJ. Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet 1990; 19: 264–79PubMedCrossRef Karbwang J, White NJ. Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet 1990; 19: 264–79PubMedCrossRef
111.
Zurück zum Zitat Baudry S, Pham YT, Baune B, et al. Stereoselective passage of mefloquine through the blood-brain barrier in the rat. J Pharm Pharmacol 1997; 49: 1086–90PubMedCrossRef Baudry S, Pham YT, Baune B, et al. Stereoselective passage of mefloquine through the blood-brain barrier in the rat. J Pharm Pharmacol 1997; 49: 1086–90PubMedCrossRef
112.
Zurück zum Zitat Czuba MA, Morgan DJ, Ching MS, et al. Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. J Pharm Sci 1991; 80: 445–8PubMedCrossRef Czuba MA, Morgan DJ, Ching MS, et al. Disposition of the diastereoisomers quinine and quinidine in the ovine fetus. J Pharm Sci 1991; 80: 445–8PubMedCrossRef
113.
Zurück zum Zitat Nicholl DD, Edwards G, Ward SA, et al. The disposition of primaquine in the isolated perfused rat liver: stereoselective formation of the carboxylic acid metabolite. Biochem Pharmacol 1987; 36: 3365–9PubMedCrossRef Nicholl DD, Edwards G, Ward SA, et al. The disposition of primaquine in the isolated perfused rat liver: stereoselective formation of the carboxylic acid metabolite. Biochem Pharmacol 1987; 36: 3365–9PubMedCrossRef
114.
Zurück zum Zitat Baune B, Flinois JP, Furlan V, et al. Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5. J Pharm Pharmacol 1999; 51: 419–26PubMedCrossRef Baune B, Flinois JP, Furlan V, et al. Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5. J Pharm Pharmacol 1999; 51: 419–26PubMedCrossRef
115.
Zurück zum Zitat Fontaine F, de Sousa G, Burcham PC, et al. Role of cytochrome P450 3A in the metabolism of mefloquine in human and animal hepatocytes. Life Sci 2000; 66: 2193–212PubMedCrossRef Fontaine F, de Sousa G, Burcham PC, et al. Role of cytochrome P450 3A in the metabolism of mefloquine in human and animal hepatocytes. Life Sci 2000; 66: 2193–212PubMedCrossRef
116.
Zurück zum Zitat Hellgren U, Berggren-Palme I, Bergqvist Y, et al. Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. Br J Clin Pharmacol 1997; 44: 119–24PubMedCrossRef Hellgren U, Berggren-Palme I, Bergqvist Y, et al. Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. Br J Clin Pharmacol 1997; 44: 119–24PubMedCrossRef
117.
Zurück zum Zitat Lu L, Leonessa F, Baynham MT, et al. The enantioselective binding of mefloquine enantiomers to P-glycoprotein determined using an immobilized P-glycoprotein liquid chromatographic stationary phase. Pharm Res 2001; 18: 1327–30PubMedCrossRef Lu L, Leonessa F, Baynham MT, et al. The enantioselective binding of mefloquine enantiomers to P-glycoprotein determined using an immobilized P-glycoprotein liquid chromatographic stationary phase. Pharm Res 2001; 18: 1327–30PubMedCrossRef
118.
Zurück zum Zitat Humberstone AJ, Porter CJ, Edwards GA, et al. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. J Pharm Sci 1998; 87: 936–42PubMedCrossRef Humberstone AJ, Porter CJ, Edwards GA, et al. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. J Pharm Sci 1998; 87: 936–42PubMedCrossRef
119.
Zurück zum Zitat Krishna S, ter Kuile F, Supanaranond S, et al. Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. Br J Clin Pharmacol 1993; 36: 585–91PubMedCrossRef Krishna S, ter Kuile F, Supanaranond S, et al. Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. Br J Clin Pharmacol 1993; 36: 585–91PubMedCrossRef
120.
Zurück zum Zitat Ueda CT. Qunidine, chapter 23. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. 2nd ed. Vancouver: Applied Therapeutics Inc., 1993: 23-1-23-2 Ueda CT. Qunidine, chapter 23. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. 2nd ed. Vancouver: Applied Therapeutics Inc., 1993: 23-1-23-2
121.
Zurück zum Zitat Fieger H, Iredale J, Wainer IW. Enantioselective determination of hydroxychloroquine and its major metabolites in urine and the observation of a reversal in the (+)/(−)-hydroxychloroquine ratio. Chirality 1993; 5: 65–70PubMedCrossRef Fieger H, Iredale J, Wainer IW. Enantioselective determination of hydroxychloroquine and its major metabolites in urine and the observation of a reversal in the (+)/(−)-hydroxychloroquine ratio. Chirality 1993; 5: 65–70PubMedCrossRef
122.
Zurück zum Zitat Tajerzadeh H, Cutler DJ. Blood to plasma ratio of mefloquine: interpretation and pharmacokinetic implications. Biopharm Drug Dispos 1993; 14: 87–91PubMedCrossRef Tajerzadeh H, Cutler DJ. Blood to plasma ratio of mefloquine: interpretation and pharmacokinetic implications. Biopharm Drug Dispos 1993; 14: 87–91PubMedCrossRef
123.
Zurück zum Zitat Karbwang J, Bunnag D, Harinasuta T, et al. Pharmacokinetics of quinine, quinidine and cinchonine when given as combination. Southeast Asian J Trop Med Public Health 1992; 23: 773–6PubMed Karbwang J, Bunnag D, Harinasuta T, et al. Pharmacokinetics of quinine, quinidine and cinchonine when given as combination. Southeast Asian J Trop Med Public Health 1992; 23: 773–6PubMed
124.
Zurück zum Zitat Miller DR, Fiechtner JJ, Carpenter JR, et al. Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis. Arthritis Rheum 1987; 30: 567–71PubMedCrossRef Miller DR, Fiechtner JJ, Carpenter JR, et al. Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis. Arthritis Rheum 1987; 30: 567–71PubMedCrossRef
125.
Zurück zum Zitat Hedman A, Angelin B, Arvidsson A, et al. Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. Clin Pharmacol Ther 1990; 47: 20–6PubMedCrossRef Hedman A, Angelin B, Arvidsson A, et al. Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. Clin Pharmacol Ther 1990; 47: 20–6PubMedCrossRef
Metadaten
Titel
Stereoselectivity in the Pharmacodynamics and Pharmacokinetics of the Chiral Antimalarial Drugs
verfasst von
Dr Dion R. Brocks
Reza Mehvar
Publikationsdatum
01.12.2003
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 15/2003
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200342150-00004

Weitere Artikel der Ausgabe 15/2003

Clinical Pharmacokinetics 15/2003 Zur Ausgabe

Acknowledgments

Acknowledgement